Similar Stories to Drugmakers Can Keep Making Off-brand Weight-loss Drugs As Fda Backpedals on Bing News

Facing a lawsuit, the Food and Drug Administration has decided to reconsider its decision to take popular weight-loss and diabetes drugs off of the national shortage list, which will allow compounding pharmacies to continue selling cheaper copycat versions—at least for now. A trade organization representing compounding pharmacies sued the agency last week over its October 2 announcement that there was no longer a shortage of tirzepatide drugs, branded as Mounjaro for diabetes and Zepbound for weight loss.

Topics:  food   drug administration   october   mounjaro   zepbound   glp-1   december   fda   comments    a   making   weight-loss   drugs   shortage   list   pharmacies   products   compounding   popular   announcement   tirzepatide   diabetes   
BING NEWS:
  • Drugmakers can keep making off-brand weight-loss drugs as FDA backpedals
    Facing a lawsuit, the Food and Drug Administration has decided to reconsider its decision to take popular weight-loss and diabetes drugs off of the national shortage list, which will allow compounding ...
    10/15/2024 - 6:53 am | View Link
  • FDA says compounding pharmacies can keep making weight-loss med tirzepatide, for now
    Pharmacists may continue making compounded versions of the weight-loss medication tirzepatide while the U.S. Food and Drug Administration revisits its Oct. 2 decision to remove the medicine from a ...
    10/15/2024 - 6:21 am | View Link
  • FDA will reconsider decision barring copycat versions of Lilly weight loss drug
    The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and diabetes drug from its official shortage list and allow compounding ...
    10/14/2024 - 11:46 am | View Link
  • Compounding pharmacies can resume making tirzepatide as FDA reconsiders shortage
    The FDA said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of tirzepatide as it reconsiders whether the drug is in shortage.
    10/14/2024 - 9:52 am | View Link
  • Hims & Hers Stock Jumps as FDA Reconsiders Restrictions on Copycat Weight-Loss Drugs
    Hims & Hers Health shares rose Monday after the Food and Drug Administration said compounding pharmacies could continue to produce copycat weight-loss drugs while it reconsiders whether there is a ...
    10/14/2024 - 9:40 am | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News